Teflaro sales 13 million; Forest tumbles on 40% loss of Lexapro LOE

Quote

Anonymous

Guest
Teflaro® (ceftaroline fosamil), a broad-spectrum bactericidal cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia and with acute bacterial skin and skin structure infections recorded sales of $7.9 million. Teflaro was launched in March 2011.

Forest Laboratories Inc's quarterly profit plunged 40 percent as the company lost patent protection for its blockbuster Lexapro antidepressant.

Forest also lowered its fiscal-year forecast, as the company increased spending behind the marketing and development of new products designed to replace Lexapro.
 




I still cannot fathom how they ever milked 1/2 the Celexa molecule (aka Lexapro) for a few billion after Celexa went generic. Forest gives Pharma a bad name (and that takes some doing).
 




Anonymous said:
I still cannot fathom how they ever milked 1/2 the Celexa molecule (aka Lexapro) for a few billion after Celexa went generic. Forest gives Pharma a bad name (and that takes some doing).
Click to expand...
Forest Labs is to be admired for their successful promotion of two sub-optimal compounds. Celexa got slammed as a placebo in the Medical Letter when it came out. Lexapro is....they should write a book on turning a lemon into lemonade. I'd bet that their clinical trials on that drug cost $256.28 USD.
 












$13 million doesn't a even pay for reps monthly expenses let alone salaries, cars. Forest will sink next year with Teflaro without Lexapro to pay your bills.

Gigs up. Go call your mother to move back in again.
 




Top Bottom
Back
Quote